Capstone Therapeutics Corp. is a biotechnology company committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with under-served medical conditions. Previously, we were focused on the development and commercialization of two product platforms: AZX100 and Chrysalin (TP508). We no longer have any interest in or rights to Chrysalin. On August 3, 2012, we entered into a joint venture, LipimetiX Development, LLC, (the “JV”) to develop Apo E mimetic peptide molecule AEM-28 and its analogs.

Research Grants show all

NIH13

Publications show all

Capstone Therapeutics has published 2 articles.

Patents show all

94Issued38Applications

Clinical Trials show all

4Phase 2

SEC Filings show all

8-K12710-Q6310-K21D1S-11

Private Funding Events

DateOfferedSoldType
2006-03-15UnknownUnknownOther (Paper Filing)